Analysts Set Invivyd, Inc. (NASDAQ:IVVD) PT at $8.00

Shares of Invivyd, Inc. (NASDAQ:IVVD) have been given an average recommendation of “Hold” by the six analysts that are presently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and three have assigned a buy recommendation to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $8.00.

IVVD has been the subject of a number of research analyst reports. BTIG Research reaffirmed a “buy” rating on shares of Invivyd in a research report on Tuesday, July 7th. HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of Invivyd in a research note on Monday, June 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Invivyd in a report on Wednesday, April 29th. Finally, Wall Street Zen lowered Invivyd from a “hold” rating to a “strong sell” rating in a report on Saturday, May 16th.

Institutional Investors Weigh In On Invivyd

A number of large investors have recently made changes to their positions in the company. Invesco Ltd. increased its position in shares of Invivyd by 190.6% during the 1st quarter. Invesco Ltd. now owns 108,999 shares of the company’s stock valued at $66,000 after purchasing an additional 71,485 shares during the last quarter. AQR Capital Management LLC boosted its holdings in shares of Invivyd by 2,051.0% in the first quarter. AQR Capital Management LLC now owns 410,711 shares of the company’s stock worth $249,000 after buying an additional 391,617 shares during the last quarter. Marshall Wace LLP bought a new stake in Invivyd during the second quarter valued at approximately $158,000. Jane Street Group LLC bought a new stake in Invivyd during the second quarter valued at approximately $147,000. Finally, Vanguard Group Inc. increased its holdings in Invivyd by 46.7% during the third quarter. Vanguard Group Inc. now owns 5,762,894 shares of the company’s stock valued at $6,339,000 after buying an additional 1,834,970 shares during the last quarter. 70.36% of the stock is currently owned by institutional investors.

Invivyd Stock Up 2.0%

Shares of IVVD stock opened at $0.82 on Thursday. The company has a 50 day moving average price of $1.02 and a 200-day moving average price of $1.52. Invivyd has a 52 week low of $0.48 and a 52 week high of $3.07. The firm has a market capitalization of $240.70 million, a PE ratio of -2.64 and a beta of 0.67.

Invivyd (NASDAQ:IVVD) last released its quarterly earnings data on Thursday, May 14th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.05). Invivyd had a negative net margin of 138.90% and a negative return on equity of 53.48%. The company had revenue of $13.74 million for the quarter, compared to analysts’ expectations of $18.04 million. Analysts anticipate that Invivyd will post -0.5 earnings per share for the current year.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.